Transfusion · 2026
Usefulness of pegfilgrastim for allogeneic peripheral blood stem cell collection from healthy donors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shimizu Tomoshige, Jo Tomoyasu, Yoshinaga Noriyoshi, Sakamoto Takashi, Matsui Hiroyuki, Kitawaki Toshio, Kanda Junya, Nishikori Momoko, Yamashita Kouhei, Nagao Miki, Takaori-Kondo Akifumi, Arai Yasuyuki
Аннотация
BACKGROUND: Granulocyte colony-stimulating factor (G-CSF)-based mobilization is essential for peripheral blood stem cell (PBSC) collection for allogeneic transplantation. Conventional daily G-CSF requires repeated dosing and dose adjustment and often necessitates leukapheresis over multiple consecutive days, increasing donor burden. Single-dose pegfilgrastim has emerged as an alternative; however, real-world data on its impact on CD34+ cell collection in healthy donors remain limited.
STUDY DESIGN AND METHODS: Healthy related or unrelated donors who received either a single dose of pegfilgrastim or daily filgrastim and subsequently underwent PBSC collection at Kyoto University Hospital between July 2014 and September 2025 were included. CD34+ cell harvest outcomes and donor burden were compared.
RESULTS: A total of 39 donors were analyzed (20 pegfilgrastim, 19 filgrastim), with comparable baseline characteristics. At the start of leukapheresis, peripheral blood white blood cell counts were significantly higher in the pegfilgrastim group. Pegfilgrastim achieved greater total CD34+ cell yield (median 398.0 × 106 vs. 302.4 × 106 cells, p = .025) and higher yields per 10 L of processed blood (median 407.8 × 106 vs. 302.4 × 106 cells, p = .032). Single-session leukapheresis was more frequent with pegfilgrastim (95.0% vs. 63.2%, p = .002), and the estimated processing time required to collect 2 × 106/kg CD34+ cells was shorter (median 62.7 vs. 111.1 min, p = .040). No severe adverse events were observed.
DISCUSSION: These findings suggest that single-dose pegfilgrastim enables more efficient PBSC collection with reduced donor burden and may represent a practical mobilization strategy in healthy allogeneic donors.
STUDY DESIGN AND METHODS: Healthy related or unrelated donors who received either a single dose of pegfilgrastim or daily filgrastim and subsequently underwent PBSC collection at Kyoto University Hospital between July 2014 and September 2025 were included. CD34+ cell harvest outcomes and donor burden were compared.
RESULTS: A total of 39 donors were analyzed (20 pegfilgrastim, 19 filgrastim), with comparable baseline characteristics. At the start of leukapheresis, peripheral blood white blood cell counts were significantly higher in the pegfilgrastim group. Pegfilgrastim achieved greater total CD34+ cell yield (median 398.0 × 106 vs. 302.4 × 106 cells, p = .025) and higher yields per 10 L of processed blood (median 407.8 × 106 vs. 302.4 × 106 cells, p = .032). Single-session leukapheresis was more frequent with pegfilgrastim (95.0% vs. 63.2%, p = .002), and the estimated processing time required to collect 2 × 106/kg CD34+ cells was shorter (median 62.7 vs. 111.1 min, p = .040). No severe adverse events were observed.
DISCUSSION: These findings suggest that single-dose pegfilgrastim enables more efficient PBSC collection with reduced donor burden and may represent a practical mobilization strategy in healthy allogeneic donors.